Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 15, 2006. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific insider trading activity and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific transaction by Mr. J. Clarke:
- Option Exercise: On November 13, 2006, Mr. Clarke exercised options over 13,609 Ordinary shares granted on November 21, 1996, under the SmithKline Beecham Employee Share Option Plan 1991.
- Exercise Price: GBP 8.34 per share.
- Share Sale: On the same date, 13,609 shares were sold at an average price of GBP 13.74 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director share transactions.
Investor Verification Points
- Verify the total number of shares held by Mr. J. Clarke post-transaction to assess remaining exposure.
- Confirm the timing of the option grant (1996) relative to the exercise date to understand the vesting period.
- Review the difference between the exercise price (GBP 8.34) and the sale price (GBP 13.74) to calculate the immediate realized gain.